Quick Answer
LIXTE BIOTECHNOLOGY HOLDINGS, INC. reported Operating Income of -$5.11 million for fiscal year 2025.
LIXTE BIOTECHNOLOGY HOLDINGS, INC. Operating Income — Annual History
| Fiscal Year | Operating Income | YoY Change |
|---|---|---|
| 2025 | -$5.11M | -43.0% |
| 2024 | -$3.57M | +29.8% |
| 2023 | -$5.09M | +19.3% |
| 2022 | -$6.31M | +6.1% |
| 2021 | -$6.72M | -105.7% |
| 2020 | -$3.27M | -31.2% |
| 2019 | -$2.49M | -16.5% |
| 2018 | -$2.14M | -18.1% |
| 2017 | -$1.81M | +15.2% |
| 2016 | -$2.13M | +19.3% |
| 2015 | -$2.65M | -10.1% |
| 2014 | -$2.40M | -74.8% |
| 2013 | -$1.37M | +34.7% |
| 2012 | -$2.11M | -12.7% |
| 2011 | -$1.87M | -111.9% |
| 2010 | -$881.7K | — |
Quarterly Operating Income
| Quarter Ending | Operating Income | YoY | QoQ |
|---|---|---|---|
| September 30, 2025 | -$1.80M | -83.2% | -132.5% |
| June 30, 2025 | -$774.8K | +23.2% | -9.6% |
| March 31, 2025 | -$706.9K | +26.9% | +28.1% |
| September 30, 2024 | -$983.3K | +4.0% | +2.6% |
| June 30, 2024 | -$1.01M | +39.6% | -4.4% |
| March 31, 2024 | -$966.9K | +29.4% | +5.6% |
| September 30, 2023 | -$1.02M | +30.7% | +38.7% |
| June 30, 2023 | -$1.67M | -8.0% | -21.9% |
- LIXTE BIOTECHNOLOGY HOLDINGS, INC. showed a decrease of -43.0% in Operating Income compared to the prior fiscal year.
- Over the 2010–2025 period, LIXTE BIOTECHNOLOGY HOLDINGS, INC.’s operating income has declined by 479.3% (from -$881.7 thousand to -$5.11 million).
- The most recent figure is from LIXTE BIOTECHNOLOGY HOLDINGS, INC.’s fiscal year 2025 report (Form 10-K), filed with the SEC on March 31, 2026.
- All figures are sourced from SEC EDGAR XBRL filings, last verified June 17, 2026.
Last verified: